Table 1.
Patient characteristics
| Patient ID | ECOG | Sex | Race | Histology | PD-L1 expression (%) | Response to pembrolizumab | Autoimmune disorder | Survival status |
|---|---|---|---|---|---|---|---|---|
| PD1-001 | 1 | Female | Caucasian | Poorly differentiated | 0 | PD | No | Deceased |
| PD1-003 | 0 | Female | Caucasian | Poorly differentiated | 10 | PD | Polymyositis, myocarditis, hepatitis | Deceased |
| PD1-019 | 0 | Female | Asian | Squamous | 5 | SD | Diabetes type I, pancreatitis, hepatitis | Deceased |
| PD1-020 | 0 | Male | Caucasian | Squamous | 0 | PD | No | Deceased |
| PD1-027 | 1 | Female | Caucasian | Poorly differentiated | 0 | PD | No | Deceased |
| PD1-004 | 1 | Female | Caucasian | Squamous | 80 | PR | Hepatitis | Alive |
| PD1-005 | 0 | Male | Black | Squamous | 80 | CR | No | Alive |
| PD1-011 | 0 | Male | Caucasian | Squamous | 80 | PR | No | Alive |
| PD1-017 | 0 | Male | Caucasian | Poorly differentiated | 10 | PR | No | Alive |
| PD1-032 | 0 | Male | Caucasian | Poorly differentiated | 15 | PR | No | Alive |
PD, progressive disease; SD, stable disease; PR, partial response; CR, complete response. ECOG, Eastern Cooperative Oncology Group.